Episode 53
53: A Landmark Year for Alzheimer Disease
December 17, 202153m 41s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Anton Porsteinsson, MD, director, Alzheimer's Disease Care, Research and Education Program (AD-CARE); William B. and Sheila Konar Professor of Psychiatry, School of Medicine and Dentistry, University of Rochester. He shared his perspective on the progress made in Alzheimer disease in 2021, from the first approval since 2003 to the agents moving through the pipeline and the improved understanding of AD pathology, and offered a look into what the future may hold.
Episode Breakdown:
In this episode, we spoke with Anton Porsteinsson, MD, director, Alzheimer's Disease Care, Research and Education Program (AD-CARE); William B. and Sheila Konar Professor of Psychiatry, School of Medicine and Dentistry, University of Rochester. He shared his perspective on the progress made in Alzheimer disease in 2021, from the first approval since 2003 to the agents moving through the pipeline and the improved understanding of AD pathology, and offered a look into what the future may hold.
Episode Breakdown:
- 1:15 – Agents in late-stage development in Alzheimer disease
- 10:30 – Additional agents with promise in the pipeline
- 17:00 – Neurology News Minute
- 21:05 – The next big step forward in Alzheimer
- 31:10 – Learning from prior failures, improving diagnostics
- 45:00 – Looking back on the progress in 2021, and ahead to 2022
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- American Academy of Sleep Medicine Publishes Updated Recommendations on Referring OSA Candidates for Surgery
- Phase 3 Study of BXCL501 for Agitation in Alzheimer Disease Initiated
- FDA Accepts Ublituximab Biologics License Application for Relapsing MS
Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.